Advertisement
Screener

Century Therapeutics, Inc. (IPSC) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Century Therapeutics, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Century Therapeutics, Inc. return tang equity for the quarter ending 2026-06-30 was -48.23%, a change of -36.89% year-over-year.
  • Century Therapeutics, Inc. return tang equity for the quarter ending 2026-03-31 was -41.45%, a change of -32.14% year-over-year.
  • Century Therapeutics, Inc. return tang equity for the quarter ending 2025-12-31 was -6.21%, a change of 74.60% year-over-year.
  • Century Therapeutics, Inc. return tang equity for the quarter ending 2025-09-30 was -15.43%, a change of 52.59% year-over-year.
  • Century Therapeutics, Inc. return tang equity for fiscal 2025 was -6.03%, a change of 72.41% from fiscal 2024.
  • Century Therapeutics, Inc. return tang equity for fiscal 2024 was -78.44%, a change of -4.46% from fiscal 2023.
  • Century Therapeutics, Inc. return tang equity for fiscal 2023 was -73.98%, a change of -30.73% from fiscal 2022.
  • Century Therapeutics, Inc. return tang equity for fiscal 2022 was -43.25%, a change of -19.07% from fiscal 2021.
Available history
2020-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-48.23%-$109.79M$227.62M
2026-03-31-41.45%-$107.78M$260.02M
2025-12-31-6.21%-$9.57M$154.21M
2025-09-30-15.43%-$26.48M$171.62M
2025-06-30-11.35%-$23.28M$205.17M
2025-03-31-9.31%-$21.95M$235.71M
2024-12-31-80.80%-$126.57M$156.64M
2024-09-30-68.02%-$129.89M$190.96M
2024-06-30-60.54%-$131.39M$217.01M
2024-03-31-75.03%-$133.47M$177.88M
2023-12-31-73.98%-$136.67M$184.75M
2023-09-30-58.82%-$128.96M$219.23M
2023-06-30-51.29%-$126.99M$247.57M
2023-03-31-44.98%-$124.68M$277.18M
2022-12-31-43.25%-$130.93M$302.74M
2022-09-30-38.60%-$127.44M$330.21M
2022-06-30-34.28%-$122.7M$357.95M
2022-03-31-29.74%-$114.99M$386.66M
2021-12-31-24.18%-$95.82M$396.24M
2021-09-30-19.66%-$83.16M$422.99M
2021-06-30-15.69%-$70.22M$447.6M
2021-03-3167.99%-$62.25M-$91.56M
2020-12-3150.35%-$53.58M-$106.41M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-6.03%-$9.58M$158.94M
2024-12-31-78.44%-$126.57M$161.36M
2023-12-31-73.98%-$136.67M$184.75M
2022-12-31-43.25%-$130.93M$302.74M
2021-12-31-24.18%-$95.82M$396.24M
2020-12-3150.35%-$53.58M-$106.41M

Similar stocks

Stock NameCountryMarket CapPE Ratio
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
Liminatus Pharma, Inc. (LIMN)United States$0.282B
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Ocugen, Inc. (OCGN)United States$0.343B-6.34
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05